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Several enzymes of the metabolic pathways responsible for metabolism of cytosolic ribonucleotides and deoxyribonucleotides
are located in mitochondria. Studies described in this paper suggest dysfunction of the mitochondria to aﬀect these metabolic
pathways and limit the available levels of cytosolic ribonucleotides and deoxyribonucleotides, which in turn can result in aberrant
RNA and DNA synthesis. Mitochondrial dysfunction has been linked to genomic instability, and it is possible that the limiting
eﬀect of mitochondrial dysfunction on the levels of nucleotides and resulting aberrant RNA and DNA synthesis in part can be
responsible for this link. This paper summarizes the parts of the metabolic pathways responsible for nucleotide metabolism that
can be aﬀected by mitochondrial dysfunction.
1.Introduction
Mitochondria are semiautonomous organelles present in
almost all eukaryotic cells in quantities ranging from a
single copy to several thousand per cell. Important mito-
chondrial functions include ATP production by oxidative
phosphorylation, β-oxidation of fatty acids, and metabolism
of amino acids and lipids. Furthermore, mitochondria have
a prominent role in apoptosis. Mitochondrial dysfunction
has been linked to genomic instability, and mutations in
mitochondrial DNA (mtDNA) have been shown in a wide
array of tumors [1, 2].
The focus of this paper is on the consequences of
mitochondrial function for metabolism of cytosolic ribonu-
cleotides and deoxyribonucleotides. Several of the rate-
limiting steps of these metabolic pathways take place in
the mitochondria and can be aﬀected by the ﬁtness of the
organelle. Disturbance of mitochondrial function therefore
has the potential to aﬀect the cytosolic levels of ribonu-
cleotides and deoxyribonucleotides, which in turn can aﬀect
the genomic stability.
Where deoxyribonucleotides are exclusively destined
for DNA synthesis in the form of deoxyribonucleotides
triphosphates (dNTP), ribonucleotides have a multitude
of uses in RNA synthesis in the form of ribonucleotide
triphosphates (rNTP), as chemical energy transporters in
the form of adenine-5-triphosphate (ATP) and to form the
basisofsecondmessengermolecules.Disruptionoftheintra-
cellular levels of deoxyribonucleotides or ribonucleotides is
unfavorable for the cell. Imbalance of the dNTP pools can
induceavarietyofgeneticchangessuchasbasesubstitutions,
frameshift mutations, delay of replication fork progression
and DNA replication, as well as increase the frequency of
fragile sites [3–9]. Decreased levels of rNTP pools inhibits
RNA synthesis, likely by inhibiting the initiation frequency
of RNA polymerase I, and thereby inhibiting the synthesis
of rRNA [10]. Furthermore, inhibition of purine and
pyrimidine synthesis induces a potentially p53-mediated cell
cycle arrest and inhibits proliferation, which ultimately leads
to increased cytotoxicity [11–14].
The total number of genes encoding mitochondrial pro-
teins is estimated to 1013 [15]. Mitochondria contain their
own autonomous genome, which encodes 13 polypeptides.
The remainder is encoded by nuclear DNA and imported
into mitochondria. Mitochondrial dysfunction can therefore
be the result of mutations in either the mitochondrial or2 Journal of Nucleic Acids
nuclear genome. Mitochondria are enclosed by a double-
membrane where the electron transport chain (ETC) main-
tainsanelectrochemicalpotentialgradientbetweentheinter-
membrane space and the matrix of the mitochondria. The
ETC is constituted of four membrane bound enzyme com-
plexes (complex I-IV) and two electron carriers (ubiquinon
and cytochrome c) and is located in the inner membrane of
themitochondria.Theelectrochemicalgradientisutilizedby
the ATP synthase (complex V) to generate ATP by oxidative
phosphorylation.
The 13 polypeptides encoded by mtDNA constitute
critical subunits of the ETC and ATP synthase [16, 17].
Mitochondrial dysfunction resulting from mutations in the
mitochondrial genome therefore aﬀects the function of the
ETC, the electrochemical gradient and the generation of ATP
by oxidative phosphorylation whereas mitochondrial dys-
functions caused by mutations in nuclear encoded proteins
can aﬀect all mitochondrial processes.
Several studies have demonstrated a correlation between
diﬀerent types of mitochondrial dysfunction and aberrant
synthesis of cytosolic ribonucleotides and deoxyribonu-
cleotides [18–21]. In the following, we will review mito-
chondrial pathways that are involved in the metabolism of
cytosolic ribonucleotides and deoxyribonucleotides. Exempt
from this paper is any direct link between aberrant produc-
tion of ATP from oxidative phosphorylation and synthesis
of cytosolic ribonucleotides and deoxyribonucleotides. Most
metabolic pathways are dependent on ATP and a review of
these processes in response to an insuﬃcient ATP synthesis is
outside the scope of this paper.
2.DihydroorotateDehydrogenase
LinksMitochondria tothede novo
PyrimidneBiosynthesis
The ﬂavoenzyme dihydroorotae dehydrogenase (DHOD-
Hase) catalyzes the conversion of dihydroorotate to orotate
by oxidation, making DHODHase an integral step of the
de novo synthesis of pyrimidines. Subsequent catalytic steps
convert orotate into uridine monophosphates which can be
further converted to UTP and CTP, and ultimately, dTTP
and dCTP. DHODHase is located in the inner membrane
of the mitochondria with the active site facing the inner
membrane[22].DHODHaseisfunctionallyconnectedtothe
ETC by a ﬂavin prosthetic group that couples dihydroorotate
oxidation to respiratory ubiquinone reduction [23]. From
ubiquinol, the reduced form of ubiquinone, the ﬂow of
electrons continues through the ETC (see Figure 1).
As a result of the connection between DHODHase and
the ETC, it has been suggested that any dysfunction of the
ETC-lack of oxygen, presence of inhibitors or mutations of
complex III and IV, would entail impairments of the de novo
UMP synthesis and a subsequent decrease in the de novo
synthesis of pyrimidines and, thereby, the cytosolic ribonu-
cleotide pool [24]. Along this line, it has been suggested that
mitochondrial dysfunction will lead to an imbalance of the
cytosolic dNTP pool caused by inhibition of the DHODHase
[25]. The relationship between DHODHase and the ETC
has been described using the two ETC inhibitors, rotenone
and sodium cyanide, on mitochondria isolated from rat
liver, kidney, and heart. Rotenone inhibits the transfer
of electrons from complex I of the ETC to ubiquinone
whereas sodium cyanide inhibits complex IV. In isolated
mitochondria, treatment with sodium cyanide abolishes the
activity of DHODHase while treatment with rotenone does
not seem to have an eﬀect [24]. This indicates that only
an inhibition or impairment of the complexes of ETC that
causes a build up of ubiquinol has an inhibitory eﬀect on
the DHODHase. A functional ETC is not only necessary
for correct function of DHODHase, but also for correct
localization of the protein. DHODHase is encoded by nDNA
and the import into the membrane of the mitochondria is
dependent on a targeting signal in the N-terminal segment
of the protein. It has been demonstrated that import of rat
DHODHase into yeast mitochondria was abolished by an
uncoupling of the mitochondrial membrane indicating the
requirement of a membrane potential for correct positioning
of DHODHase [26].
The importance of a functional DHODHase for the de
novo synthesis of pyrimidines is emphasized by the eﬀect
of inhibitors of DHODHase. Leﬂunomide and brequinar
are two examples of DHODHase inhibitors that bind to
the quinone-binding site of DHODHase, thereby, blocking
interaction between ubiquinone and the ﬂavin prostethic
group of DHODHase [27]. Treatment of human lympho-
cytes with leﬂunomide or brequinar arrests the cells in G1
phase and inhibits both RNA and DNA synthesis [28–30].
The inhibitory eﬀects are suppressed by addition of uridine,
which can be salvaged to UMP whereby the de novo synthesis
of pyrimidines is bypassed. Treating the human leukemic
cell line CCRF.CEM with leﬂunomide or brequninar cause
a signiﬁcant reduction in the levels of CTP and UTP, while
thelevelsofpurinenucleotidesareunaﬀectedaftertreatment
with lefunomide or increased after treatment with brequinar
[31].
Chloramphenicol is an antimicrobial agent that inhibits
mitochondrial protein synthesis [32]. Treatment of cells
with chloramphenicol therefore mimics an mtDNA induced
mitochondrialdysfunctionandimpairedETCactivity.Treat-
ment of chick embryo cells with chloramphenicol inhibits
a c t i v i t yo fD H O D H a s ea sw e l la sc e l lg r o w t h[ 33]. Growth
of Ehrlich Ascites tumor cells under hypoxic conditions
inhibited the ETC and caused reduced activity of the
DHODHase and resulted in a G1 arrest [34]. For both the
chloramphenicol treated chick embryo cells and hypoxic
Ehrlich Ascites tumor cells, growth inhibition was reversed
by addition of pyrimidines to the growth media. This
indicates that mitochondrial dysfunction aﬀecting the ETC
has an inhibitory eﬀect on DHODHase activity that is
comparable to inhibition with leﬂunomide or brequinar.
This conclusion is substantiated by the fact that cultured
mammalian cells devoid of mtDNA are auxotrophic for
pyrimidines and must be routinely grown in the presence of
a uridine supplement [21].
An inhibition of DHODHase has been demonstrated
to result in decreased levels of pyrimidne ribonucleotides
and has been proposed to result in imbalanced dNTPJournal of Nucleic Acids 3
pools [24, 25]. The activity of DHODHase is coupled to
the activity of ETC and mitochondrial dysfunctions aﬀecting
the activity of the ETC is therefore likely to aﬀect the
activity of the DHODase and the de novo synthesis of
pyrimidine ribo- and deoxyribonucleotides. In concordance,
we have previously demonstrated the human cancer cells
depleted of mtDNA had lowered dNTP levels when com-
pared with parental cell lines with functional mtDNA [18].
Furthermore, unpublished data indicates that a leﬂunomide-
mediated inhibition of DHODHase in a human cervical
cancer cell line results in decreased levels of dTTP and dCTP
(data not shown). It is therefore possible that damage to the
ETC can aﬀect the cytosolic levels of pyrimidine nucleotides
through the activity of the DHODHase.
3. MitochondrialProduction of One-Carbon
UnitsLinksMitochondria to the de novo
Purine Biosynthesis
Serine is a major source of one-carbon units required for
the synthesis of glycine, thymidylate, methionine, several
methylation reactions, and, most important for this paper,
purine synthesis (see Figure 1). In mammals, serine is
derivedfromthedietandissynthesizedfromglycolysisvia3-
phosphoglycerate. Serine is reversibly converted into glycine
in a process catalyzed by serine hydroxymethyltransferase
(SHMT) [35]. There are two isoenzymes of SHMT, a
cytosolic (cSHMT) and a mitochondrial (mSHMT) [36]. It
is generally believed that the process catalyzed by mSHMT
is the primary pathway for conversion of serine to glycine.
This is substantiated by studies using Chinese Hamster
Ovary (CHO) cells where loss of mSHMT activity was
demonstrated to result in an accumulation of intracellular
serine leading to a 15-fold higher serine concentration.
Nevertheless, the net ﬂux through cSHMT was still in the
direction of serine synthesis [37]. Furthermore, CHO cells
deﬁcient in mSHMT activity are glycine auxotrophs [38],
and the auxotrophy can be suppressed by transfection with a
human version of mSHMT, suggesting that the primary role
of mSHMT but not cSHMT is to generate glycine [39].
During the mSHMT catalyzed conversion of serine to
glycine, a methyl group is transferred from serine to tetrahy-
drofolate (THF), yielding glycine and 5,10-methylene-
THF [35]. Within the mitochondrial compartment, 5,10-
methyleneTHF is converted into formate in a series of
enzymatic conversions initiated by the conversion of 5,10-
methylene-THF into 5-methyl-THF and subsequently into
10-formyl-THF, in NAD+-dependent reactions catalyzed
by the bifunctional enzyme methylene-THF-dehydrogenase.
10-formyl-THF is converted into formate in a reaction
catalyzed by 10-formyl-THF-synthase and formate can be
exported from mitochondria to the cytosol, where it is
converted back to 10-formyl-THF in an ATP dependent
reaction catalyzed by 10-formyl-THF-synthetase. Cytosolic
10-formyl-THF is an essential one-carbon unit donor for
the de novo synthesis of purine nucleotides, requiring 2
moles of 10-formyl-THF per mole of purine ring formed
Reviewed in [40, 41]. The role of mitochondrial formate is
demonstrated using radioactive labeled variants of formate
and serine in murine ﬁbroblasts and human breast cancer
cells. Labeled one-carbon units could be traced into both
RNA and DNA and their origin could be traced to originate
from serine imported to the mitochondria and exported as
formate [19, 42].
The contribution of mitochondrial formate to purine
synthesis is not existing in all cell types. The rate limit-
ing enzyme methylene-THF-dehydrogenase is expressed in
transformed and embryonic cell lines as well as undiﬀerenti-
ated cells from bone marrow, thymus, and spleen but not in
diﬀerentiated tissue from brain, heart, skeletal muscle, liver,
or kidney where the mitochondrial production of formate
therefore is absent [43]. Even though a supply of mitochon-
drial produced formate is not necessarily an indispensible
carbon source for purine synthesis, a blocked production
of formate is demonstrated to inhibit cell-cycle progression
in mouse ﬁbroblasts and in phytohemagglutin stimulated
splenocytes accompagnied by signiﬁcant decreases in both
cellular deoxyribonucleotide and ribonucleotide pools [19,
20]. Furthermore, mouse embryos that do not express
methylene-THF-dehydrogenase and therefore are unable to
generate mitochondrial formate are not viable [44], under-
liningtheimportanceofthemitochohondrialproductionfor
formate on nucleotide synthesis in exposed cells.
The proteins necessary for mitochondrial production
of one-carbon units and export of formate are all nuclear
encoded.Thiseliminatesthepossibility ofanydirectinvolve-
ment of mitochondrial encoded proteins in this pathway. It
is, however, possible that mutations of the mitochondrial
genome that will result in a decreased function of the ETC,
turnover of intermediates or the production of ATP can
have an indirect eﬀect on the mitochondrial production of
one-carbon units and formate export. Loss of mtDNA and
resulting damaged ETC has been argumented to cause a
decrease in mitochondrial NADH oxidation to NAD+ and a
resulting inhibition on mitochondrial processes dependent
on NAD+ [45]. Since methylene-THF-dehydrogenase is a
NAD+-dependent enzyme, lack of NAD+ could limit the
production of mitochondrial formate, and it is therefore
possible that loss of mtDNA indirectly can inﬂuence the
production of mitochondrial formate and thereby cytosolic
purine synthesis. By comparing human osteosarcoma cells
devoid of mtDNA with their parental mtDNA containing
cells, it was found that both cell lines grew equally well in
complete and glycine-deﬁcient media, demonstrating that
the cells without mtDNA were not glycine auxotrophs [19].
This indicates that loss of mtDNA does not abolish purine
synthesis,however,itdoesnotremovethepossibilitythatloss
of mtDNA limits the production of mitochondrial formate
and results in lowered levels of cytosolic purine levels.
4. Mitochondrial Productionof Nitric Oxide
IndirectlyAffects the Nucleotide Metabolism
Nitric oxide (NO) is an uncharged and highly diﬀusible
inorganic signal molecule with a wide variety of roles in
the organism. Mitochondrial nitric oxide synthase (mtNOS)4 Journal of Nucleic Acids
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Figure 1: Overview of metabolic pathways responsible for nucleotide metabolism that can be aﬀected by mitochondrial dysfunction.
The illustration depicts the outer and inner mitochondrial membrane. Complexes of the electron transport chain are illustrated with
boxes marked with numerals I-IV. Boxes marked with V depict ATP synthase. Darkened boxes illustrate enzymes of interest. Upper left:
Dihydroorotate(DHODHase)isanintegralenzymeinthedenovosynthesisofpyrimidines.Theenzymeislocatedintheinnermitochondrial
membrane and its activity is dependent on an active electron transport chain. Upper right: Mitochondrial nitric oxide synthase (mtNOS)
createsNOinaCa
2+ dependentreaction.Theenzymeislocatedintheinnermitochondrialmembranewhereitinteractswithbothcomplexes
I and IV of the electron transport chain. The activity of mtNOS is linked to the mitochondrial membrane potential. NO has the potential
to inhibit the activity of Complexes I, III, and IV, but also ribonucleotide reductase in the cytosol. Lower: Illustration of the mitochondrial
production of one-carbon units and mitochondrial export of formate. See text for details.
is a constitutively expressed nuclear encoded enzyme that
generates NO in a Ca2+-dependent reaction. Furthermore,
judging from proven properties of other nitric oxide syn-
thases, production of NO by mtNOS is likely regulated by
acetylation and phosphorylation of the enzyme [reviewed
in 46]. MtNOS is located in the inner membrane of the
mitochondria, [46] where it physically interacts with both
complexes I and IV of the ETC (See Figure 1)[ 47, 48]. NO
has at sub-micromolar concentrations been demonstrated to
act as a competitive inhibitor of complex IV and to inhibit
electron transport at complex III. Furthermore, complex I is
inhibited after long-term exposure to NO [49–51]A sar e s u l t
of the inhibitory eﬀects of NO on diﬀerent sites of the ETC,
both the activities of DHODHase and ATP synthase have
been demonstrated to be inhibited in response to increased
NO levels [52, 53]. Both the localization of mtNOS and
the inhibitory eﬀects of NO on the generation of ATP by
oxidative phosphorylation have lead to the general belief
that the purpose of mtNOS is to regulate the oxygen uptake
according to the energy requirement of the cell in a short-
term fashion. Besides a direct regulatory eﬀect on oxygen
uptake, NO has in turn the potential of indirectly inhibiting
the synthesis of nucleotides through its inhibitory eﬀects on
the DHODHase as discussed previously.
Eﬄux of NO from the mitochondria is maximal after
treatment with oligomycin and minimal after treatment of
CCCP. Treatment with oligomycin inhibits the ATP synthase
and produces a hyper polarization of the mitochondrial
membrane. Conversely, treatment with CCCP uncouples the
membrane. This led to the hypothesis that mtNOS is a
voltage-dependent enzyme, whose activity is regulated by
mitochondrial membrane potential [54, 55]. Very little is
known about any possible deregulation of mtNOS resulting
from mitochondrial dysfunction. If the activity of mtNOSJournal of Nucleic Acids 5
is linked to the membrane potential and a depolarization
inactivates the enzyme, damage to the ETC will therefore
inactivate the protein. Conversely inhibition of the ATP
synthase leading to a hyperpolarization will activate mtNOS.
Examples of mutations aﬀecting the ATP synthase are
known. The ATP synthase has been demonstrated to be
severely impaired in patients with mutated versions of the
mtDNA encoded ATPase 6 subunit of the ATP synthase [56].
The inﬂuence of this and other damages to the ATP synthase
on mtNOS has, however, not been investigated.
Nitric oxide produced by mtNOS is most likely not
constricted to the mitochondria, but may serve a role
in the cytosolic compartment. Eﬄux of NO from the
mitochondria to the cytosol has been demonstrated. This
eﬄux is correlated with the membrane potential of the
mitochondria and has been hypothesized to function as a
mitochondrial signal to the cytosol, reporting on the energy
status of the mitochondria [54, 55]. By using mitochondria
extracted from diﬀerent rat tissue, the fraction of cytosolic
NO resulting from a mitochondrial eﬄux was calculated
to range from 61% in heart tissue to 18% in brain tissue
[54] .T h er o l eo fa ne ﬄux of NO from the mitochondria
into the cytosol is unknown however, it has been suggested
that it may serve a regulatory role in cell metabolism and
proliferation [54, 57]. In this case, an imbalance of the dNTP
pool demonstrated in cells with a mitochondrial dysfunction
could be caused by a resulting error in this pleiotropic
regulation of cell metabolism. However, NO have several
targets in the cellular compartment, and depending on the
amount of NO emanating from the mitochondria, these
could provide a more direct relationship between the mito-
chondria and dNTP balance. During the de novo pathway
the reduction of ribonucleotides to 2-deoxyribonucleotides
is catalyzed by the rate limiting enzyme ribonucleotide
reductase. The reductase constitutes the major regulator of
the de novo dNTP synthesis [58] mediating a reduction of
the 2-hydroxy group in the ribose of the ribonucleotides
[59]. The resulting deoxyribonucleotides dADP, dCDP, and
dGDP undergo phosphorylation yielding the corresponding
dNTPs;however,dTTPissynthesizedfromdCDP,anddUDP
and requires additional steps. Ribonucleotide reductase has
been demonstrated to be directly inhibited by NO resulting
in a depletion of dNTP proportional to the amount of
NO. Treatment of a human lymphoblastoid cell line with
diﬀerent NO prodrugs induced a dNTP imbalance that
was comparable to the dNTP proﬁle after treatment with
the ribonucleotide reductase inhbitor hydroxy urea [60].
Inhibition of the reductase by NO was demonstrated to
induceadecreaseofdATPanddCTPlevelswhereasthedTTP
levels were transiently increased [60].
5. Flux of Deoxyribonucleotides between
Mitochondria and the Cytosol Is Unlikely to
CauseaCytosolicdNTP Imbalance
The cellular content of rNTP and dNTP is sequestered into
two pools, a mitochondrial and a cytosolic, separated by the
mitochondrial double membrane [61]. The existence of a
mitochondrial salvage pathway of dNTP is well-established
whereas the existence of a mitochondrial de novo pathway of
dNTPisdebated[62].Themitochondrialinnermembraneis
impermeable to charged molecules, and consequently, there
isno directexchangeofrNTP or dNTP between thecytosolic
and mitochondrial compartments. However, several studies
have shown a facilitated transport of dNTP between the
two compartments reviewed in [62]. Furthermore, export
of dNTP from mitochondria and incorporation into nDNA
has been demonstrated [63]. It can, therefore, be speculated
that the mitochondrial production of dNTP complements
the cytosolic dNTP pools and dysfunction of mitochondrial
dNTP synthesis results in a cytosolic dNTP imbalance.
Both de novo and salvage pathways carry out synthesis
of cytosolic dNTP, while only the salvage pathway has
been demonstrated in mitochondria. The replication of
mtDNA is not synchronized with the synthesis of nDNA
[64] and therefore this organelle requires a constant supply
of dNTP. Mitochondria are able to synthesize dNTP by
a speciﬁc salvage pathway where imported deoxyribonu-
cleosides are phosphorylated by the two rate-determining
deoxyribonucleoside kinases: thymidine kinase 2 (TK2) and
deoxyguanosine kinase (dGK) yielding deoxyribonucleoside
mono-phosphates, which in turn can be further phospho-
rylated to their corresponding di- and triphosphates or be
dephosphorylated to deoxyribonucleosides again by mito-
chondrial deoxyribonucleotidases [65, 66]. The presence
of a mitochondrial located ribonucleotide reductase has
been proposed [62, 66], opening for the possibility of a
mitochondrial de novo synthesis of dNTP. The contribution
of this pathway to the mitochondrial and cytosolic pool of
dNTP is however unknown.
Export of deoxyribonucleotides from the mitochondrial
tothecytosoliccompartmenthasbeendemonstrated.Incells
lacking essential enzymes of the cytosolic salvage pathway,
an exogenous source of labeled thymidine was imported
into the mitochondria and phosporylated exclusively by the
mitochondrial salvage pathway, resulting in a mitochondrial
pool of labeled dTTP. Eﬄux to the cytosolic compartment
and incorporation of labeled dTTP into nDNA could
be demonstrated, conﬁrming an export of mitochondrial
deoxyribonucleotides. Even though the cells lacked a func-
tional cytosolic salvage pathway the contribution of the
labeled dTTP only constituted a fraction of the cytosolic
pool of dNTP, indicating a strong dominance of dNTP
produced by the de novo pathway, demonstrating that the
mitochondrial contribution to the cytosolic pool of dNTP is
negligible [63].
In nondividing tissue, loss of function mutations of
TK2 has been demonstrated to result in mitochondrial
dNTP imbalance and consequently deletions and depletions
of mtDNA [67]. Furthermore, even minor impairment of
TK2 activity has been reported to result in a decreased
mitochondrial dNTP pool [68]. Using a human cervical
cancer cell line that can be induced to express lower levels
of TK2, it was possible to reduce the activity of TK2 in
the cell with 47% [69]. The activity was assayed by the
ability of TK2 to phosphorylate thymidine-β-D-arabinoside.
Decreasing the activity of the mitochondrial salvage pathway6 Journal of Nucleic Acids
by lowering the level of TK2 did not alter the cytosolic dNTP
pools, supporting the small contribution of mitochondrial
dNTP export to the cellular dNTP pool [69].
Whereas the mitochondrial export of dNTP, most likely
is an insigniﬁcant contribution to the cytosolic dNTP pools,
import of dNTP to the mitochondria is essential for the
ﬁdelity of mtDNA. In cycling cells, the majority of the
intramitochondrial deoxynucleotides are synthesized in the
cytosol and imported into mitochondria [63]. The p53
inducible small subunit of the ribonucleotide reductase
p53R2 is believed to allow de novo synthesis of dNTP outside
the S-phase in response to DNA damage [70]. Mutations
o fp 5 3 R 2h a v eb e e nd e m o n s t r a t e dt or e s u l ti nm t D N A
depletion, likely caused by insuﬃcient mitochondrial dNTP
pools [71]. This indicates that mitochondria is dependent of
cytosolic dNTP in all phases of cell cycle.
In summary, published data from the literature show
that export of mitochondrial-produced dNTP is negligible
compared to the cytosolic dNTP synthesis and the ﬂux
of dNTP is most likely in the direction of from the
cytosol to the mitochondria. Furthermore, inhibition of
the mitochondrial salvage pathway has no eﬀect on the
cytosolic dNTP pools. Together, this strongly suggests that
dysfunction of mitochondrial salvage, or potentially de
novo, synthesis of dNTP is unlikely to cause a cytosolic
dNTP imbalance by deﬁcient export or excessive import of
deoxyribonucleotides.
6. Conclusion
In this paper we describe three mitochondrial pathways
involved in the synthesis of cytosolic rNTP and dNTP.
These three pathways encompass (1) DHODHase-mediated
conversion of dihydroorotate to orotate, a rate limiting
step of de novo synthesis of pyrimidines; (2) export of
mitochondrial one carbon units in the form of formate,
used in the production of cytosolic purine nucleotides; and
(3) mitochondrial produced NO acting as an eﬀector with
bothintramitochondrialandcytosolictargetsinvolvedinthe
cytosolic synthesis of rNTP and dNTP.
The mitochondrial production and export of formate
diverge from the pathways involving DHODHase and mito-
chondrial NO. All components responsible for mitochon-
drial production and export of formate are nuclear encoded
and the pathway is sensitive to mutations in the nuclear
genes encoding these. However, even though the pathway
can be limited by comprehensive damage to the ETC,
the pathway is most likely substrate-dependent and not
regulated by the overall activity of the mitochondria. In
contrast, the activity of DHODHase is directly dependent
on the activity of the ETC and the membrane potential.
In this regard, the activity of DHODHase reﬂects the
activity of the mitochondria. Even though DHODHase is
nuclear encoded, the ETC consists of both mitochondrial
and nuclear encoded subunits. A degradation of mtDNA
as seen in a multitude of pathological conditions including
cancer [1, 2], or as demonstrated in aged tissue [72]w i l l
therefore aﬀect the activity of DHODHase and consequently
the synthesis of pyrimidine nucleotides. In contrast, mito-
chondrial export of formate and related purine synthesis
will likely be unaﬀected by nothing less than a complete
degradation of mtDNA and the ETC. NO produced from
mtNOS targets both the DHODHase and ATPase and is
proposed to be a metabolic feedback mechanism regulated
by the mitochondrial membrane potential. By inhibiting
the DHODHase, mtNOS indirectly aﬀects the de novo
synthesis of pyrimidines. MtNOS also releases NO into
the cytosolic compartment and can potentially target the
ribonucleotide reductase and thereby inhibit the major
regulator of the de novo synthesis of dNTP. It was demon-
strated that mtNOS is activated by hyper polarization of
the mitochondrial membrane. A mitochondrial dysfunction,
like damage to the ATP synthase, that allows an excessive
build up of mitochondrial membrane potential is therefore
likely to activate mtNOS whereas a general degradation
of mtDNA and/or the ETC leads to a depolarization of
the mitochondrial memebrane and inactivate the enzyme.
The eﬀect of especially DHODHase, but also mtNOS
and to some extent mitochondrial production of formate,
is dependent on the activity of ETC and mitochondrial
membrane potential. In functional cells, this pathway prob-
ably constitutes at feedback mechanism, where synthesis of
RNA and DNA is regulated by the mitochondrial activity.
However, in a pathological context, this relationship has the
potential of aﬀecting the genomic stability of the nuclear
genome. Mutations aﬀecting the activity of the ETC can
lead to a detrimental eﬀect on the cytosolic dNTP levels,
and in turn imbalanced dNTP pools can cause genetic
instability in the nuclear genome. In accordance, we have
demonstrated that human cell lines devoid of mtDNA
showed decreased and imbalanced levels of dNTP as well
as increased frequency of chromosomal instability compared
to parental cell lines with functional mtDNA [18, 73].
Chromosomal instability has been demonstrated to occur
in human osteosarcoma cell lines devoid of mtDNA. Fur-
thermore, the cells were demonstrated to have tumorigenic
properties measured by an increased anchorage independent
growth when compared to parental cells with functional
mtDNA.Itwasreportedthatthereintroductionoffunctional
mitochondria with mtDNA could suppress the tumorigenic
phenotype [74]. These observations and others deﬁne a
role for dysfunctional mitochondria in the progression of
cancer. It will be important to further elucidate the role of
the mitochondrial function on the dNTP regulation in the
detrimental relationship between dysfunctional mitochon-
dria and cancer due to the known mutagenic eﬀects of dNTP
imbalance.
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